Home Compare HIK.L vs STMN.SW
Stock Comparison · Valuation-led comparison

Hikma Pharmaceuticals vs Straumann Holding: Which Stock Looks Stronger in 2026?

Hikma Pharmaceuticals holds the cleaner structural position, with valuation as the main driver and stability adding further support. Straumann does not offset that deficit through any equally strong structural edge elsewhere. Both sides have seen trend damage — neither carries a clear market edge right now. With both trends damaged, the structural comparison carries most of the weight here.

The comparison is based on similar long-term financial trajectories, not sector labels. Both peer scores are relative to the STOXX 600 universe, making them directly comparable.

Updated 2026-08-16

Most of the separation is still concentrated in valuation. The overall score gap is 17 points in favour of Hikma Pharmaceuticals PLC.

Trajectory Similarity
0.74
Similar
Peer-set rank: #5
within Hikma Pharmaceuticals PLC's functional peer set

These two companies are linked by measured long-term financial trajectory similarity within the selected peer universe.

The pair sits on a clearly comparable long-term path, though it is not a near-twin match.

The match is driven mainly by capital structure and margin consistency.

Similarity drivers
capital structuremargin consistency
How to read the score
0.85–1.00 · Very similar0.70–0.84 · Similar0.55–0.69 · Moderately similarbelow 0.55 · Loose match
Peer-Relative Score
HIK.L
Hikma Pharmaceuticals PLC
53
Peer-Score
Signal qualitylow
Peer basis: STOXX 600
vs
STMN.SW
Straumann Holding AG
36
Peer-Score
Signal qualitylow
Peer basis: STOXX 600

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

Pricing shapes this comparison more than a broad operating gap.

Dimension spread: HIK.L vs STMN.SW Profitability 59 68 Stability 30 16 Valuation 85 30 Growth 19 17 HIK.L STMN.SW
Gap Ranking
#1 Valuation +55
#2 Stability +14
#3 Profitability +9
#4 Growth +2
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for HIK.L and STMN.SW Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer HIK.LSTMN.SW Relative valuation Structural strength

The two profiles are relatively close, but the price setup still leans toward Hikma Pharmaceuticals PLC.

Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.

Relative Position vs Comparable Companies
Valuation
On valuation, Hikma Pharmaceuticals PLC ranks near the top of the group; Straumann Holding AG sits in the weaker half.
Stability
Neither side looks especially strong on stability, though Hikma Pharmaceuticals PLC still ranks somewhat higher.
Valuation — Dominant Gap
HIK.L
85
STMN.SW
30
Gap+55in favour of HIK.L

The multiple-based pricing edge comes from a forward P/E that is 18.5 turns lower.

What keeps the gap from being one-sided

Straumann Holding AG still carries lower volatility exposure — that difference is real enough to prevent the comparison from becoming one-sided.

What this means for the comparison

Valuation is the clearest driver, and stability also supports Hikma Pharmaceuticals PLC's broader structural position.

Explore full peer positioning in AssetNext

Break down the HIK.L vs STMN.SW comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Similar valuation-driven comparisons

Explore how HIK.L and STMN.SW each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.